PPDTM CorEvitasTM Chronic Hand Eczema (CHE) Drug Safety and Effectiveness Registry

NCT07598058 | Not Yet Recruiting

• 1 other identifier: CorEvitas-CHE-515
• Study Type: observational
• Target: 2,000
• Locations: 0 countries
• Sites: N/A

Brief Summary

The design is a prospective, observational registry for subjects with CHE under the care of dermatology or other qualified healthcare provider. Longitudinal data are collected from both subjects and their treating provider during routine clinical encounters using a structured and standardized data collection method

Conditions

Chronic Hand Eczema

Outcome Measures

Primary Outcomes (2)

• CHE Disease Epidemiology and presentation

  The major clinical outcome include an assessment of the epidemiology of CHE Disease; to better understand the presentation and natural history.

  Every 6 months for 10 years

• CHE Disease management, and outcomes

  The major clinical outcome include an assessment of the epidemiology of CHE Disease; to better understand the management and outcomes.

  Every 6 months for 10 years

Interventions

Observational (Non-Interventional) Registry OTHER

This is an observational (non-interventional) registry

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Subjects enrolled in this registry will be treated according to routine clinical care; treatments are prescribed at the provider's discretion and the decision to treat the subject with a drug is made prior to and independently of study participation. The clinician will determine subject visit schedules according to routine practice, patient needs, and local standard of care (SoC)

You may qualify if:

• To be eligible to participate in this registry, an individual must meet all of the following criteria:
• Diagnosed with moderate-to-severe CHE by a dermatologist or other qualified healthcare provider at the time of enrollment and initiating an eligible medication.
• Is at least 18 years of age or older and has attained the legal age for consent to procedures involved in the research, under the applicable law of the jurisdiction in which the research is being conducted at the time of enrollment
• Is willing and able to consent to participation in the registry
• Is willing and able to complete registry-related forms electronically via personal devices.
• Is willing and able to provide the information (first name, last name, email address, language and primary time zone) required to create an account to allow you to complete registry forms via a personal device;
• Is willing and able to provide Personal Information (full legal name, sex, date of birth, home address zip or postal code and email address or phone number at a minimum) if required based on registry location and applicable laws and regulations.

You may not qualify if:

• An individual who meets any of the following criteria will be excluded from participation in the registry:
• \) Is participating or planning to participate in a blinded clinical trial for a CHE drug

Sponsors & Collaborators

• CorEvitas: lead

MeSH Terms

Interventions

Registries

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Records; Organization and Administration; Health Services Administration; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Central Study Contacts

Cathy Cheney

CONTACT

+1 508 408 5433; corevitasregistrytrials@corevitas.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 13, 2026
• First Posted: May 20, 2026
• Study Start (Estimated): May 29, 2026
• Primary Completion (Estimated): December 31, 2099
• Study Completion (Estimated): December 31, 2099
• Last Updated: May 20, 2026

Record last verified: 2026-05